Scalper1 News
Valeant Pharmaceuticals International (VRX) sought to soothe investor worries Tuesday morning, while the short seller who provoked its recent scandal moved on to attacking fellow specialty drugmaker Mallinckrodt (MNK) in dueling TV interviews with Mallinckrodt’s CEO. Valeant’s management held a conference call Tuesday morning that brought little new information. CEO J. Michael Pearson said that after Valeant cut ties with disgraced pharmacy Scalper1 News
Scalper1 News